Abbott Laboratories Aktie News

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.

Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long-term expected annualized returns of at least 10%. Dividend growth for the Kings remains subdued at 5.81% for 2025, trailing the 2024 rate of 6.32%.

Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite cost-saving initiatives and the Hess acquisition, leading to subdued dividend growth. Dividend increases in January will generally be modest, with select companies like Fastenal, S&P Global, and C...

Abbott Laboratories (ABT) earns a buy rating for its operational resilience, robust fundamentals, and strong dividend growth despite headwinds. ABT delivered double-digit EPS growth, solid Medical Devices performance, and increased its dividend by 7%, demonstrating ongoing financial strength. The pending $21B Exact Sciences acquisition is expected to be accretive, further strengthening ABT's gr...

Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PFA – is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies A PDA requiring treatment is present in approximately 20% of premature infants1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbot...

CVS Health is slowly righting the ship after several challenging years. Abbott Laboratories' strong business should improve thanks to an acquisition.

Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.